Cargando…

Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?

Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that may benefit from early diagnosis and intervention. Therefore, there is a need to identify early biomarkers of AD using non-invasive techniques such as functional magnetic resonance imaging (fMRI). Recently, novel approaches to...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarapicchia, Vanessa, Mazerolle, Erin L., Fisk, John D., Ritchie, Lesley J., Gawryluk, Jodie R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826397/
https://www.ncbi.nlm.nih.gov/pubmed/29515434
http://dx.doi.org/10.3389/fnagi.2018.00039
_version_ 1783302346650943488
author Scarapicchia, Vanessa
Mazerolle, Erin L.
Fisk, John D.
Ritchie, Lesley J.
Gawryluk, Jodie R.
author_facet Scarapicchia, Vanessa
Mazerolle, Erin L.
Fisk, John D.
Ritchie, Lesley J.
Gawryluk, Jodie R.
author_sort Scarapicchia, Vanessa
collection PubMed
description Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that may benefit from early diagnosis and intervention. Therefore, there is a need to identify early biomarkers of AD using non-invasive techniques such as functional magnetic resonance imaging (fMRI). Recently, novel approaches to the analysis of resting-state fMRI data have been developed that focus on the moment-to-moment variability in the blood oxygen level dependent (BOLD) signal. The objective of the current study was to investigate BOLD variability as a novel early biomarker of AD and its associated psychophysiological correlates. Method: Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 database from 19 participants with AD and 19 similarly aged controls. For each participant, a map of BOLD signal variability (SD(BOLD)) was computed as the standard deviation of the BOLD timeseries at each voxel. Group comparisons were performed to examine global differences in resting state SD(BOLD) in AD versus healthy controls. Correlations were then examined between participant SD(BOLD) maps and (1) ADNI-derived composite scores of memory and executive function and (2) neuroimaging markers of cerebrovascular status. Results: Between-group comparisons revealed significant (p < 0.05) increases in SD(BOLD) in patients with AD relative to healthy controls in right-lateralized frontal regions. Lower memory scores and higher WMH burden were associated with greater SD(BOLD) in the healthy control group (p < 0.1), but not individuals with AD. Conclusion: The current study provides proof of concept of a novel resting state fMRI analysis technique that is non-invasive, easily accessible, and clinically compatible. To further explore the potential of SDBOLD as a biomarker of AD, additional studies in larger, longitudinal samples are needed to better understand the changes in SDBOLD that characterize earlier stages of disease progression and their underlying psychophysiological correlates.
format Online
Article
Text
id pubmed-5826397
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58263972018-03-07 Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? Scarapicchia, Vanessa Mazerolle, Erin L. Fisk, John D. Ritchie, Lesley J. Gawryluk, Jodie R. Front Aging Neurosci Neuroscience Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that may benefit from early diagnosis and intervention. Therefore, there is a need to identify early biomarkers of AD using non-invasive techniques such as functional magnetic resonance imaging (fMRI). Recently, novel approaches to the analysis of resting-state fMRI data have been developed that focus on the moment-to-moment variability in the blood oxygen level dependent (BOLD) signal. The objective of the current study was to investigate BOLD variability as a novel early biomarker of AD and its associated psychophysiological correlates. Method: Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 database from 19 participants with AD and 19 similarly aged controls. For each participant, a map of BOLD signal variability (SD(BOLD)) was computed as the standard deviation of the BOLD timeseries at each voxel. Group comparisons were performed to examine global differences in resting state SD(BOLD) in AD versus healthy controls. Correlations were then examined between participant SD(BOLD) maps and (1) ADNI-derived composite scores of memory and executive function and (2) neuroimaging markers of cerebrovascular status. Results: Between-group comparisons revealed significant (p < 0.05) increases in SD(BOLD) in patients with AD relative to healthy controls in right-lateralized frontal regions. Lower memory scores and higher WMH burden were associated with greater SD(BOLD) in the healthy control group (p < 0.1), but not individuals with AD. Conclusion: The current study provides proof of concept of a novel resting state fMRI analysis technique that is non-invasive, easily accessible, and clinically compatible. To further explore the potential of SDBOLD as a biomarker of AD, additional studies in larger, longitudinal samples are needed to better understand the changes in SDBOLD that characterize earlier stages of disease progression and their underlying psychophysiological correlates. Frontiers Media S.A. 2018-02-21 /pmc/articles/PMC5826397/ /pubmed/29515434 http://dx.doi.org/10.3389/fnagi.2018.00039 Text en Copyright © 2018 Scarapicchia, Mazerolle, Fisk, Ritchie and Gawryluk. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Scarapicchia, Vanessa
Mazerolle, Erin L.
Fisk, John D.
Ritchie, Lesley J.
Gawryluk, Jodie R.
Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?
title Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?
title_full Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?
title_fullStr Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?
title_full_unstemmed Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?
title_short Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?
title_sort resting state bold variability in alzheimer’s disease: a marker of cognitive decline or cerebrovascular status?
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826397/
https://www.ncbi.nlm.nih.gov/pubmed/29515434
http://dx.doi.org/10.3389/fnagi.2018.00039
work_keys_str_mv AT scarapicchiavanessa restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus
AT mazerolleerinl restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus
AT fiskjohnd restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus
AT ritchielesleyj restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus
AT gawrylukjodier restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus